TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23460154

Group type: EXPERIMENTAL
Intervention: ECCO2R
Number of subjects: 20
Study: 23460155

Group type: EXPERIMENTAL
Intervention: Subsegmental WA%
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Emphysema
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Increases in WA% between bronchial segments
Number of subjects: 983
Study: 23461618

Group type: EXPERIMENTAL
Intervention: Noninvasive serum fibrosis indices calculated at the time of RFA
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Age-platelet index (API) ≤7
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Serum alpha-fetoprotein (AFP)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Serum bilirubin
Number of subjects: 246
Study: 23463272

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 23463422

Group type: EXPERIMENTAL
Intervention: Intraventricular tissue plasminogen activator (rtPA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (external ventricular drainage alone)
Number of subjects: 24
Study: 23464850

Group type: EXPERIMENTAL
Intervention: Pancreaticoduodenectomy with standardized pathological protocol (quality protocol)
Number of subjects: 150
Study: 23465037

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN) 25 mg once weekly to 50 mg twice weekly
Number of subjects: 1853

Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 1853
Study: 23465456

Group type: EXPERIMENTAL
Intervention: Vacuum-assisted wound closure (VAWCM)
Number of subjects: 28
Study: 23466185

Group type: EXPERIMENTAL
Intervention: Ventana fenestrated stent grafts
Number of subjects: 15
Study: 23466307

Group type: EXPERIMENTAL
Intervention: Tremelimumab (15 mg/kg IV every 90 days until tumor progression or severe toxicity)
Number of subjects: 20
Study: 23468161

Group type: EXPERIMENTAL
Intervention: Positive bacterial culture after sonication in permanent implants
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Positive bacterial culture after sonication in temporary implants
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Bacterial organisms identified
Number of subjects: 84
Study: 23468307

Group type: EXPERIMENTAL
Intervention: Subcutaneous omacetaxine 1.25 mg/m² twice daily days 1-14 every 28 days until hematologic response, then days 1-7 every 28 days as maintenance.
Number of subjects: 46
Study: 23468538

Group type: EXPERIMENTAL
Intervention: Intravascular cooling after intra-arterial reperfusion therapy (IAT)
Number of subjects: 20
Study: 23468548

Group type: EXPERIMENTAL
Intervention: Carotid artery stenoses and occlusions
Number of subjects: 2187

Group type: EXPERIMENTAL
Intervention: Nonstenotic carotid plaques
Number of subjects: 2187

Group type: EXPERIMENTAL
Intervention: Supratentorial intracranial artery stenoses and occlusions
Number of subjects: 2187

Group type: EXPERIMENTAL
Intervention: Large-artery atherosclerosis
Number of subjects: 2187
Study: 23468941

Group type: EXPERIMENTAL
Intervention: Metformin monotherapy (500 mg/day, up-titrated weekly to a maximum 2,000 mg/day for 16 weeks)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Metformin monotherapy
Number of subjects: 371
Study: 23469326

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Total WRAADDS
Number of subjects: 67
Study: 23471087

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 1,200 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study: 23471467

Group type: EXPERIMENTAL
Intervention: COPD current smokers
Number of subjects: 68

Group type: COMPARATOR
Intervention: COPD ex-smokers
Number of subjects: 68

Group type: COMPARATOR
Intervention: Healthy smokers
Number of subjects: 68

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 68
Study: 23471754

Group type: EXPERIMENTAL
Intervention: Analgesia Nociception Index (ANI)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Surgical Pleth Index (SPI)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Bispectral Index (BIS)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Heart Rate (HR)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Mean Arterial Pressure (MAP)
Number of subjects: 25
Study: 23473415

Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 0
Study: 23473656

Group type: EXPERIMENTAL
Intervention: Quality of Well Being Scale (QWB)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Lenert utility score
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Heinrich-Carpenter Quality of Life Scale (QOLS)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Positive and Negative Syndrome Scale (PANSS)
Number of subjects: 350
Study: 23473846

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 6
Study: 23474038

Group type: EXPERIMENTAL
Intervention: Migalastat hydrochloride (50mg, 150mg, and 250mg QOD)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Migalastat hydrochloride (150mg or 250mg QOD)
Number of subjects: 9
Study: 23474348

Group type: EXPERIMENTAL
Intervention: Farletuzumab with chemotherapy (carboplatin and taxane)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Farletuzumab with chemotherapy
Number of subjects: 54
Study: 23474588

Group type: EXPERIMENTAL
Intervention: Long-term glycemia, traditional cardiovascular disease (CVD) risk factors, and ascending aortic stiffness measured with magnetic resonance imaging.
Number of subjects: 879
Study: 23474796

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (APM)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Diagnostic arthroscopy (placebo surgery)
Number of subjects: 140
Study: 23474805

Group type: EXPERIMENTAL
Intervention: Plerixafor and granulocyte colony-stimulating factor
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Auto-SCT (ASCT)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Post ASCT
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Follow up at 42 months
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of MDS/AML
Number of subjects: 49
Study: 23475281

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m(2)) and carboplatin (AUC = 6 mg/mL·min) followed by maintenance pemetrexed
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Maintenance pemetrexed
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: EGFR wild-type patients
Number of subjects: 109
Study: 23475406

Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release (PR; 50-250 mg b.i.d.)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Tapentadol (PR and IR combined)
Number of subjects: 136
Study: 23477369

Group type: EXPERIMENTAL
Intervention: Miniaturized laparoscope-holder (Light Endoscope Robot [LER])
Number of subjects: 16
Study: 23477704

Group type: EXPERIMENTAL
Intervention: Semi-quantitative pregnancy test at home
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: User comprehension survey
Number of subjects: 300
Study: 23477833

Group type: EXPERIMENTAL
Intervention: Cixutumumab (6 mg/kg, intravenous) and temsirolimus (25 mg, intravenous flat dose) weekly in 6-week cycles for IGF-1R-positive soft-tissue sarcoma (group A)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Cixutumumab (6 mg/kg, intravenous) and temsirolimus (25 mg, intravenous flat dose) weekly in 6-week cycles for IGF-1R-positive bone sarcoma (group B)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Cixutumumab (6 mg/kg, intravenous) and temsirolimus (25 mg, intravenous flat dose) weekly in 6-week cycles for IGF-1R-negative bone and soft-tissue sarcoma (group C)
Number of subjects: 162
Study: 23478952

Group type: EXPERIMENTAL
Intervention: Telaprevir (750 mg every 8 hours for 7 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Methadone alone (without telaprevir)
Number of subjects: 16
Study: 23479303

Group type: EXPERIMENTAL
Intervention: Obese group
Number of subjects: 79

Group type: COMPARATOR
Intervention: Normal-weight group
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Linear regression analysis
Number of subjects: 79
Study: 23479676

Group type: EXPERIMENTAL
Intervention: Total i.v. anaesthesia controlled remotely (Montreal)
Number of subjects: 20
Study: 23480759

Group type: EXPERIMENTAL
Intervention: Intermittent-high dose oral calcitriol 12 μg/day for 3 days per week for up to 3 months (n=2)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Chemotherapeutic drugs (5-fluorouracil, Mitomycin C, and Leucovorin) for 3 cycles (n=3)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High dose calcitriol in combination with chemotherapeutic drugs (n=4)
Number of subjects: 9
Study: 23480899

Group type: EXPERIMENTAL
Intervention: Posttrial enrollment campaign 1
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Posttrial enrollment campaign 2
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Women who re-enrolled
Number of subjects: 100
Study: 23482470

Group type: EXPERIMENTAL
Intervention: Pupillometer-based objective chromatic perimetry (short-wavelength stimulus, peak 485 nm, light intensity 40 cd/m(2))
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pupillometer-based objective chromatic perimetry (long-wavelength stimulus, peak 640 nm, light intensity 40 cd/m(2))
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Pupillometer-based objective chromatic perimetry
Number of subjects: 29

Group type: COMPARATOR
Intervention: Dark-adapted chromatic Goldmann perimetry
Number of subjects: 29
Study: 23483536

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA)
Number of subjects: 59806

Group type: COMPARATOR
Intervention: Non-ASA NSAIDs and acetaminophen
Number of subjects: 59806
Study: 23483678

Group type: EXPERIMENTAL
Intervention: CP-870,893 (0.1 mg/Kg or 0.2 mg/Kg) combined with carboplatin and paclitaxel
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CP-870,893 (0.2 mg/Kg)
Number of subjects: 32
Study: 23484617

Group type: EXPERIMENTAL
Intervention: Diet intervention (16 weeks dietary programme with formula products and counselling)
Number of subjects: 192
Study: 23484671

Group type: EXPERIMENTAL
Intervention: Home visit intervention by certified nurse-midwives
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard prenatal care
Number of subjects: 130
Study: 23484829

Group type: EXPERIMENTAL
Intervention: Germline mutations in TP53
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Family members who are not carriers
Number of subjects: 0
Study: 23484911

Group type: EXPERIMENTAL
Intervention: Oral fat load of 700 kilocalories per m² of body surface area at 83% fat after an 8-h fast.
Number of subjects: 817
Study: 23485031

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Sum of individual components of MetS
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Dichotomized variables of MetS
Number of subjects: 461

Group type: COMPARATOR
Intervention: MetS definitions
Number of subjects: 461
Study: 23485794

Group type: EXPERIMENTAL
Intervention: 3-month active rehabilitation program consisting of cardiovascular training, knee and hip progressive resistance training, and neuromuscular training.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Adverse events during the rehabilitation program.
Number of subjects: 48
Study: 23487538

Group type: EXPERIMENTAL
Intervention: Vandetanib therapy
Number of subjects: 1
Study: 23488447

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 30 (BIAsp 30) therapy
Number of subjects: 57000
Study: 23489023

Group type: EXPERIMENTAL
Intervention: Vemurafenib (240-360 mg twice a day, escalated to 720 mg twice a day)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 3
Study: 23489259

Group type: EXPERIMENTAL
Intervention: GFAP-BDP level
Number of subjects: 215
Study: 23489534

Group type: EXPERIMENTAL
Intervention: Group I: Rapid streptokinase
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Group II: Slow streptokinase
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Group III: High-dose (100 mg) t-PA
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Group IV: Half-dose (50 mg) t-PA, slow infusion (6 h) without bolus
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Group V: Low-dose (25 mg) t-PA, slow infusion (6 h) without bolus
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Group V vs Groups I-IV
Number of subjects: 182
Study: 23489536

Group type: EXPERIMENTAL
Intervention: Papillary muscle infarction (PMI) present
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Lateral wall infarction
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Lateral wall infarct size
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Mitral annular diameter
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: LV end-diastolic diameter
Number of subjects: 153

Group type: COMPARATOR
Intervention: PMI presence
Number of subjects: 153

Group type: COMPARATOR
Intervention: Angiographic culprit vessel
Number of subjects: 153
Study: 23489912

Group type: EXPERIMENTAL
Intervention: Sequential finger-thumb opposition test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapid pace walk test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pelli-Robson contrast sensitivity test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One-legged stance test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Snellen visual acuity test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marottoli method (functional neck range of motion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whispered voice test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Range of motion and strength testing
Number of subjects: 0
Study: 23490650

Group type: EXPERIMENTAL
Intervention: BMS-690514 (200mg daily)
Number of subjects: 90
Study: 23490654

Group type: EXPERIMENTAL
Intervention: Sequential arm S treated with 5-fluorouracil and leucovorin (LV5FU2) followed by FOLFOX (LV5FU2+oxaliplatin) and then FOLFIRI (LV5FU2+irinotecan)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Combination arm C that begins directly with FOLFOX followed by FOLFIRI
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Sequential arm S
Number of subjects: 410

Group type: COMPARATOR
Intervention: Combination arm C
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 410
Study: 23491522

Group type: EXPERIMENTAL
Intervention: HbA1c variability (measured as intraindividual SD of HbA1c values)
Number of subjects: 8260

Group type: EXPERIMENTAL
Intervention: Average HbA1c (HbA1c-MEAN)
Number of subjects: 8260

Group type: EXPERIMENTAL
Intervention: Both HbA1c parameters (HbA1c-MEAN and HbA1c-SD) above the median
Number of subjects: 8260

Group type: EXPERIMENTAL
Intervention: Both HbA1c parameters (HbA1c-MEAN and HbA1c-SD) below the median
Number of subjects: 8260
Study: 23493136

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg orally once daily combined with chemotherapy (5-fluorouracil, folinic acid, and either oxaliplatin or irinotecan)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg orally once daily combined with chemotherapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Regorafenib in combination with chemotherapy
Number of subjects: 45
Study: 23493999

Group type: EXPERIMENTAL
Intervention: Preoperative ECD
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Lower ECD at 6 months
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Coefficient of variation at 6 months
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: HEX values at 6 months
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Most recent CV or HEX values
Number of subjects: 72
Study: 23494041

Group type: EXPERIMENTAL
Intervention: 4 g of omega-3 fatty acids daily (840 mg eicosapentaenoic acid/2520 mg docosahexaenoic acid) for 6 months
Number of subjects: 17
Study: 23494984

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (600/100 mg twice daily)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic model
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bayesian estimates of individual darunavir parameters and ritonavir
Number of subjects: 75
Study: 23497046

Group type: EXPERIMENTAL
Intervention: CPAP therapy for 1 month
Number of subjects: 67
Study: 23497305

Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin™) in combination with XELOX or mFOLFOX6
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin™) in combination with FOLFIRI
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin™)
Number of subjects: 150
Study: 23497334

Group type: COMPARATOR
Intervention: Alveolar macrophages (AMø) of smokers
Number of subjects: 61

Group type: COMPARATOR
Intervention: Differentiated THP-1 cells exposed to cigarette smoke extract
Number of subjects: 61

Group type: COMPARATOR
Intervention: Total lung macrophages from smokers
Number of subjects: 61

Group type: COMPARATOR
Intervention: AMø of smokers stimulated with poly(I:C)
Number of subjects: 61
Study: 23497336

Group type: EXPERIMENTAL
Intervention: Eltrombopag 75 mg daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Eltrombopag 100 mg daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Eltrombopag 150 mg daily
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Eltrombopag (any dose)
Number of subjects: 18

Group type: COMPARATOR
Intervention: AI chemotherapy (without eltrombopag)
Number of subjects: 18
Study: 23497349

Group type: EXPERIMENTAL
Intervention: Carbon ion therapy (4 × 10 Gy(RBE))
Number of subjects: 6
Study: 23497365

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy; 30 mg/m² docetaxel on day 1 and 8, 60 mg/m² cisplatin on day 1, and 70 mg/m² S-1 on days 1 to 14, repeated every 21 days.
Number of subjects: 35
Study: 23497415

Group type: EXPERIMENTAL
Intervention: V930 alone (Study 1)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: V930 followed by V932 (Study 2)
Number of subjects: 33
Study: 23497455

Group type: EXPERIMENTAL
Intervention: LPS 1 ng/kg intravenously
Number of subjects: 294
Study: 23497524

Group type: EXPERIMENTAL
Intervention: Calf muscle neuromuscular electrical stimulation (NMES)
Number of subjects: 11
Study: 23497558

Group type: EXPERIMENTAL
Intervention: Ex vivo tacrolimus perfusion at a concentration of 20 ng/ml in 1000 ml Custodiol solution
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo with Custodiol alone
Number of subjects: 86
Study: 23497667

Group type: EXPERIMENTAL
Intervention: Drug-related problems (DRPs) identified in patients presenting with NSC
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Drug-related problems (DRPs)
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Polypharmacy and certain drug classes (thiazides, antidepressants, benzodiazepines, anticonvulsants)
Number of subjects: 633
Study: 23497731

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (12-week program with a minimum requirement of 17.5 kcal/kg weekly energy expenditure)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single exercise sessions
Number of subjects: 12
Study: 23497790

Group type: COMPARATOR
Intervention: Quetiapine XR 150 mg/day (monotherapy)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Quetiapine XR 300 mg/day (monotherapy)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Quetiapine XR 150 mg/day (adjunct therapy)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Quetiapine XR 300 mg/day (adjunct therapy)
Number of subjects: 4
Study: 23498300

Group type: EXPERIMENTAL
Intervention: TV viewing
Number of subjects: 307
Study: 23499151

Group type: EXPERIMENTAL
Intervention: Office hysteroscopy
Number of subjects: 78
Study: 23499577

Group type: EXPERIMENTAL
Intervention: Hypothermia treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study: 23500182

Group type: EXPERIMENTAL
Intervention: Stimulation of hip and trunk muscles
Number of subjects: 8
Study: 23500218

Group type: EXPERIMENTAL
Intervention: iFR (instantaneous wave-free ratio)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: iFRa (iFR during adenosine administration)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: FFR (fractional flow reserve)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Adenosine administration
Number of subjects: 51
Study: 23500222

Group type: EXPERIMENTAL
Intervention: Gait speed measurement (200-m course before discharge)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Gait speed tertiles (fastest, middle, slowest)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Gait speed (0.1 m/s increase)
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Addition of gait speed to FRS, B-type natriuretic peptide levels, and comorbidity index
Number of subjects: 472
Study: 23500318

Group type: EXPERIMENTAL
Intervention: Robotic-assisted percutaneous coronary intervention using the CorPath 200 robotic system
Number of subjects: 164
Study: 23500322

Group type: EXPERIMENTAL
Intervention: Daily monitoring of B-type natriuretic peptide (BNP) levels for 60 days with a finger-stick test.
Number of subjects: 163
Study: 23500412

Group type: EXPERIMENTAL
Intervention: Argus II retinal prosthesis
Number of subjects: 0
Study: 23504355

Group type: EXPERIMENTAL
Intervention: Surgical Safety Checklist (SSC) implementation
Number of subjects: 375
Study: 23504398

Group type: EXPERIMENTAL
Intervention: Decitabine at 45 mg/m² IV over 2 hours on day 1 and 15 and panitumumab 6 mg/kg IV over 1 hour on day 8 and 22 every 28 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Decitabine and panitumumab combination
Number of subjects: 20
Study: 23504807

Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (8 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous trastuzumab (6 mg/kg)
Number of subjects: 0
Study: 23505002

Group type: EXPERIMENTAL
Intervention: Mandometer® intervention
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Nurse-led primary care clinic
Number of subjects: 143

Group type: COMPARATOR
Intervention: Hospital clinic (control)
Number of subjects: 143
Study: 23505034

Group type: EXPERIMENTAL
Intervention: High fitness level (based on estimated maximal oxygen consumption)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Low fitness level (based on estimated maximal oxygen consumption)
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Higher fitness levels
Number of subjects: 214

Group type: COMPARATOR
Intervention: Lower fitness levels
Number of subjects: 214